- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | TransCode Therapeutics, Inc. Announces Results of Special Meeting | 409 | PR Newswire | BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more... ► Artikel lesen | |
| Di | Transcode Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.02. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial | 163 | PR Newswire | No significant safety or dose limiting toxicities reported
PK data from Cohorts 1 and 2 consistent with preclinical and Phase 0 trial results
BOSTON, Feb.... ► Artikel lesen | |
| 24.01. | TransCode Therapeutics Shares Are Surging Today: What's Going On? | 15 | Benzinga.com | ||
| TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.01. | TransCode Therapeutics regains compliance with Nasdaq | 5 | Seeking Alpha | ||
| 20.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 149 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| 06.12.24 | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 11 | SEC Filings | ||
| 02.12.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.12.24 | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 7 | Benzinga.com | ||
| 02.12.24 | TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 | 2 | Seeking Alpha | ||
| 29.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split | 242 | GlobeNewswire (Europe) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 27.11.24 | TransCode Therapeutics announces $8M private offering | 3 | Seeking Alpha | ||
| 27.11.24 | TransCode Therapeutics, Inc. Announces $8 Million Private Placement | 2 | GlobeNewswire (USA) | ||
| 25.11.24 | Why Transcode Therapeutics (RNAZ) Stock Is Moving | 2 | Benzinga.com | ||
| 25.11.24 | TransCode Therapeutics to conduct reverse stock split | 15 | Seeking Alpha | ||
| 25.11.24 | TransCode Therapeutics approves reverse stock split | 3 | Investing.com | ||
| 25.11.24 | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-33 Reverse Stock Split | 236 | GlobeNewswire (Europe) | BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
| 25.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.11.24 | Transcode Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 108,40 | +2,55 % | BioNTech-Aktie: Geht's jetzt wieder hoch? | Es ist still geworden um die BioNTech-Aktie. Sie kommt seit drei Monaten nicht vom Fleck und notiert aktuell bei 119,58 US$. Ist das die Ruhe vor dem nächsten Sturm? Übernahme abgeschlossen Die letzte... ► Artikel lesen | |
| QIAGEN | 37,695 | +0,05 % | ANALYSE-FLASH: Berenberg senkt Ziel für Qiagen auf 48 Euro - 'Buy' | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 54,90 auf 48,00 Euro gesenkt und die Einstufung auf "Buy" belassen. Das vierte Quartal sei solide gewesen, auch wenn... ► Artikel lesen | |
| NOVAVAX | 7,018 | +2,86 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| PALATIN TECHNOLOGIES | 0,880 | +1,38 % | Palatin Technologies Inc. Q2 Loss Decreases, Beats Estimates | WASHINGTON (dpa-AFX) - Palatin Technologies Inc. (PTN) revealed Loss for second quarter that decreased from the same period last year and beat the Street estimates.The company's earnings came... ► Artikel lesen | |
| BRAIN BIOTECH | 2,830 | -1,05 % | EQS-News: BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Quartals-/Zwischenmitteilung
BRAIN Biotech AG: 3M GJ 24/25 - Jahresauftakt mit zweistelligem Umsatzwachstum im Kernsegment BRAINBiocatalysts... ► Artikel lesen | |
| ORGANOVO | 0,836 | -30,68 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,950 | +3,72 % | INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications | Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,660 | +6,40 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
| GENMAB | 220,50 | +1,15 % | Genmab A/S: EPKINLY (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma | Approval based on results from two Phase 1/2 EPCORE clinical trials, which demonstrated strong and durable efficacy in patients with relapsed or refractory (R/R) follicular lymphoma (FL) who... ► Artikel lesen | |
| XOMA ROYALTY | 22,200 | 0,00 % | Dividendenbekanntmachungen (03.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGRICULTURAL BANK OF CHINA LTD ADR US00850M1027 0,4001 USD 0,3897 EUR AMERICAN EXPRESS COMPANY US0258161092 0,7 USD 0,6818 EUR AUTO... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,120 | -29,29 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,515 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - February 26, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 8-K, Current Report | ||
| ORAGENICS | 0,268 | -1,68 % | Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health | ||
| LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report |
Das Unternehmen TRANSCODE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TRANSCODE THERAPEUTICS INC finden Sie auf Wallstreet Online.
